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Figure 2. Kaplan Meier curve for time to recovery from moderately bad or worse cough 
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KEY POINTS 
Question: Does a moderate dose of oral corticosteroid reduce the duration or severity of acute lower 
respiratory tract infection in non-asthmatic adults presenting to primary care? 
Findings: In this randomized trial of 401 adults with symptoms of acute lower respiratory tract infection, 
treatment with oral prednisolone 40 mg daily for 5 days compared with placebo did not significantly reduce 
the median duration of moderately bad or worse cough (5 days in each group) or the mean severity of 
symptoms between days 2 and 4 (1.99 vs 2.16 points out of 6)..  
Meaning: These findings do not support the use of oral steroids for the treatment of acute lower 26 
respiratory tract infection in the absence of asthma.  27 
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ABSTRACT 28 
Importance: Acute lower respiratory tract infection is common and often treated inappropriately in 29 
primary care with antibiotics. Corticosteroids are increasingly used but without sufficient evidence. 30 
Objective: To assess the effects of oral corticosteroids for acute lower respiratory tract infection in non-31 
asthmatic adults. 32 
Design, setting and participants: Multicenter, placebo controlled, randomized trial (July 2013 to final 33 
follow-up October 2014) in 54 family practices in England. 401 adults with acute cough and at least one 34 
lower respiratory tract symptom, not requiring immediate antibiotic treatment and no history of chronic 35 
pulmonary disease or use of asthma medication in past 5 years. Two immediately withdrew, one duplicate 36 
patient was identified. 37 
Intervention: Two 20mg prednisone tablets (n=198) or matched placebo (n=200) once daily for 5 days. 38 
Main outcomes and measures: Primary - duration of moderately bad or worse  cough (0 to 28 days; 39 
minimal clinically important difference 3.79 days) and mean symptoms’ severity on days 2 to 4 (scored 40 
from 0 (not affected) to 6 (as bad as it could be); minimal clinically important difference 1.66 units). 41 
Secondary -  duration and severity of acute lower respiratory tract infection symptoms; duration of 42 
abnormal peak flow; antibiotic consumption; adverse events. 43 
Results: Among 398 patients with baseline data (mean age 47 (SD 16.0); 63% female; 17% smokers; 77% 44 
phlegm; 70% shortness of breath; 47% wheezing; 46% chest pain; 42% abnormal peak flow): 334 (84%) 45 
provided cough duration and 369 (93%) symptoms’ severity. Median cough duration was 5 days (IQR, 3-8) 46 
in the prednisolone group and 5 days (IQR, 3-10) in the placebo group, adjusted HR 1.11 (95% CI 0.89 to 47 
1.39, P=0.36, alpha 0.05). Mean symptoms’ severities were 1.99 and 2.16, adjusted difference -0.20 (95% CI 48 
-0.40 to 0.00, P=0.05, alpha 0.001). No significant treatment effects were observed for duration or severity 49 
of acute lower respiratory tract infection symptoms, duration of abnormal peak flow, antibiotic 50 
consumption or non-serious adverse events. There were no serious adverse events. 51 
Conclusions and relevance: Oral corticosteroids should not be used for acute lower respiratory tract 52 
infection symptoms in adults without asthma as they do not reduce symptom duration or severity.  53 
Trial registration: ISRCTN57309858. 54 
Words: 350  55 
  
Page 4 of 23 
INTRODUCTION 56 
Acute lower respiratory tract infection (ALRTI), defined as an acute cough with at least one of sputum, 57 
chest pain, shortness of breath and/or wheeze,1 is one of the most common conditions managed in primary 58 
care internationally. In 2009 to 2011, an estimated 65% to 75%2,3 of patients were prescribed antibiotics, 59 
despite good evidence they do not reduce symptom duration or severity,4 and guidelines to the contrary.1 60 
Annual antibiotic prescribing costs are estimated at US$726 million in the US,5 and US$300 million for 61 
consultations and antibiotics in the UK.6  62 
 63 
Antimicrobial resistance (AMR) is one of the greatest challenges to modern public health.7 Primary care is 64 
responsible for 80% of health service antibiotic prescribing,2,8 with a high proportion regarded as 65 
unnecessary2 and contributing to AMR.9 Both US10 and UK11 national AMR action plans recommend finding 66 
alternatives to antibiotics, but none is currently proven for ALRTI in adults.  67 
 68 
Symptoms of ALRTI are similar to those of exacerbated asthma.12 Bronchial epithelial changes are similar in 69 
people with and without asthma during a RTI, with both groups showing reductions in forced expiratory 70 
volume and airways inflammation,12 and prolonged ALRTI symptoms are thought to be due to bronchial 71 
hyper-responsiveness.13 Oral and inhaled corticosteroids are highly effective for acute asthma, but US, 72 
British and European guidelines do not provide guidance on whether corticosteroids should be used for 73 
ALRTI. Despite this, US and European clinicians are increasingly using oral and inhaled steroids, with one US 74 
study14 reporting oral prednisolone use in 15% of non-asthmatic adults with ALRTI.   75 
 76 
A previous systematic review15 found insufficient evidence regarding the role of inhaled corticosteroids and 77 
found no oral corticosteroid studies for ALRTI. The aim of this study was to investigate the effects of a 78 
moderate dose of oral corticosteroids in non-asthmatic adults presenting to primary care with ALRTI.  79 
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METHODS 80 
Ethical approval, consent, study design, participant recruitment and baseline assessment 81 
Ethical approval was granted by the Central Bristol Research Ethics Committee (12/SW/0180) and all 82 
patients gave informed, written consent. The Oral Steroids for Acute Cough (OSAC) trial was a multicenter, 83 
placebo-controlled, individually randomized study, conducted between July 2013 and October 2014. Family 84 
physicians and nurses (‘recruiting clinicians’) were trained in study procedures by four centers at the 85 
Universities of Bristol, Southampton, Nottingham and Oxford. They were asked to assess eligibility in 86 
consecutive patients: aged ≥18 years; consulting for an acute (≤28 days) cough as the main symptom with 87 
at least one lower respiratory tract symptom (phlegm, chest pain, wheezing or shortness of breath) in the 88 
previous 24 hours. Patients were excluded if they: were clinically suspected to have, or their medical 89 
records showed evidence of, chronic pulmonary disease; had received any asthma medication in the past 5 90 
years; met NICE criteria for severe infection/complications;1 required same-day hospital admission; or 91 
required same day antibiotics (see Online Supplement for full list). Participants were recruited on the day 92 
of, or the day following, presentation. Following consent, demographic and clinical data were collected, 93 
including self-reported ethnicity using UK approved16 categories, to assess sample representativeness. 94 
 95 
Randomization and concealment  96 
The treatment allocation schedule was computer-generated by a statistician independent of the trial team. 97 
Randomization (1:1 ratio prednisolone:placebo) used a variable block size (4, 6, 8 and 10) and was stratified 98 
by center. Allocated medication was added to numbered participant packs by pharmacists, independent of 99 
the team. All packs were identical and centers distributed four packs to family practices at a time. Following 100 
eligibility confirmation, participants were given the next pack.  101 
 102 
Intervention and masking 103 
Participant packs contained either 10 prednisolone 20 mg oral tablets (procured GALEN Pharma GmbH, 104 
Germany) or matched (dimension, appearance and taste) placebo tablets (Piramal Healthcare Ltd, UK). 105 
Participants were asked to take two tablets once daily for five days, starting on the day of consultation, if 106 
possible before starting any antibiotics (if receiving a ‘delayed’ prescription). The dose and duration of 107 
prednisolone was selected to reflect the dose and duration known to be effective for acute asthma.17 108 
Participants, recruiting clinicians and the trial team were masked to treatment allocation until data analyses 109 
were complete. 110 
 111 
Follow up 112 
Participants were invited to report (using web or paper versions) the presence and severity of symptoms 113 
using a validated18 diary shown to be sensitive to change .19 4 Symptoms were measured using a scale from 114 
zero (no problem) to three (moderately bad) and up to six (as bad as it could be). All symptoms were 115 
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measured daily, with twice daily peak expiratory flow, for 28 days or until symptom resolution. Cough was 116 
measured for a further 28 days in case of late treatment effects. A research nurse telephoned participants 117 
weekly to support symptom diary completion. Participants were given £5 (US$6.6) shopping vouchers at 14 118 
and 28 days. Medical notes were reviewed at 3 months for new diagnoses of asthma, COPD, whooping 119 
cough and lung cancer.  120 
 121 
Primary outcomes 122 
Two primary outcomes were used. The first was duration of moderately bad or worse cough, defined as the 123 
number of days from randomization to the last day scored ≥3, prior to at least two consecutive days scored 124 
<3, up to a maximum of 28 days. This was regarded as the more important of the two primary outcomes 125 
since cough was the main presenting symptom of the illness, and it included measures of both duration and 126 
severity. The second was the mean of the six main symptom (cough, phlegm, shortness of breath, sleep 127 
disturbance, feeling generally unwell, and activity disturbance) severity scores (each scored 0-6) on days 2 128 
to 4; a mean score was calculated across the symptoms for each day and then an overall mean calculated, 129 
giving a maximum value of six. 130 
 131 
Secondary outcomes 132 
Secondary outcomes specified a priori were: total duration and severity of each symptom up to 28 days 133 
(cough, phlegm, shortness of breath, wheeze, blocked/runny nose, chest pain, fever, muscle aching, 134 
headache, sleep disturbance, feeling generally unwell, activity disturbance); duration of moderately 135 
bad/worse and any cough up to 56 days; duration of abnormal peak flow; antibiotic consumption; adverse 136 
events; re-consultation with evidence of illness deterioration; patient satisfaction with treatment; and 137 
intention to use the same treatment if it were to be available in the future (more detail about the 138 
derivation of these outcomes is provided in the Online Supplement ). Quality of life, NHS treatment and 139 
investigation costs are not reported in this article.  140 
 141 
Subgroup analyses 142 
Pre-specified potential treatment effect modifiers were: age; prior cough duration; presence of wheeze; 143 
antibiotic consumption; b-agonist consumption; smoking status; history of hay fever, asthma or eczema; 144 
new diagnoses (at 3 months) of asthma, COPD, whooping cough or lung cancer. Baseline impression of 145 
severity of illness was added as a post-hoc sub group analysis as the trial team determined it was important 146 
to differentiate between those with severe vs. mild symptoms.   147 
 148 
Sample size calculation 149 
The distributions of both primary outcomes were expected to be positively skewed, hence sample size 150 
calculations were based on the log-normal distribution. The mean (standard deviation (SD)) duration of 151 
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moderately bad or worse cough and symptom severity score (days 2 to 4) were estimated as 5.8 (4.1) days 152 
and 2.3 (1.1) units respectively.19 This corresponds to 1.56 (SD 0.64) log days (or geometric mean of 4.74 153 
days) for cough duration and 0.73 (SD 0.45) units on the log scale (or geometric mean of 2.08) for symptom 154 
severity. As there were no previous studies of oral steroids to inform the minimum clinically important 155 
difference (MCID) in both outcomes, the investigative team considered the balance of potential benefits 156 
and adverse effects, and reached a MCID consensus of 20%, corresponding to a geometric mean in the 157 
active treatment group of 3.79 days (mean 1.33 log days) in terms of duration of cough and 1.66 units 158 
(mean 0.51 log units) for symptom severity. Allowing for 20% attrition, 218 participants needed to be 159 
randomized per group to retain 174 at follow-up and achieve 90% power with a two-sided alpha of 0.05 for 160 
primary outcome one. A final achieved sample size of 174 participants per group would provide 89% power 161 
to detect a 20% reduction in symptom severity, with an adjusted two-sided alpha of 0.001 to reflect its 162 
‘second primary outcome’ status (see Online Supplement). 163 
Statistical methods 164 
Analysis of primary outcomes 165 
A pre-specified analysis plan was approved by the Trial Steering and Data Monitoring Committees and the 166 
study protocol was published before data collection had finished (see Online Supplement). All analyses 167 
were performed in Stata 13.1.20 168 
The primary comparative analyses considered patients in the groups to which they were randomized, 169 
without imputation for missing outcome data. These analyses were adjusted for center (Bristol, 170 
Nottingham, Oxford and Southampton), and the relevant baseline measure (prior cough duration (1-28 171 
days) for duration of moderately bad or worse cough; patient reported illness severity in last 24 hours for 172 
symptom severity (0 completely well – 10 extremely unwell). Time-to-event methods were used to analyze 173 
the duration of moderately bad or worse cough. Semi-parametric Cox-proportional hazard models were 174 
employed (to enable comparison with previous studies) and the assumption of proportional hazards 175 
checked by visual inspection of the log-log survival curves and calculation of the Schoenfeld residuals.21 176 
Hazard ratios were reported comparing the instantaneous rate of resolution of cough between 177 
prednisolone and placebo groups, with 95% confidence intervals (CI) and P values. In order to assist 178 
interpretation against the MCID of a 20% reduction in time to resolution, for which hazard ratios are 179 
unhelpful, parametric Weibull Accelerated Failure Time (AFT) models were used to present cough duration 180 
treatment effects as time ratios. Such models can be formulated as proportional hazards or AFT models; 181 
hence hazard ratios were also produced from the Weibull models to ensure comparability with the Cox 182 
models. 183 
Mean severity score from days 2 to 4 was considered in linear regression models. Models considered mean 184 
severity score and log mean severity score and distributional checks of residuals were undertaken to 185 
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determine the most appropriate model. Differences between the prednisolone and placebo groups are 186 
reported with 95% confidence intervals and P-values.  187 
For both primary outcomes, secondary analyses additionally adjusted for factors demonstrating imbalance 188 
at baseline (a difference >5% for binary and >0.5SDs for continuous outcomes) and for smoking, since this is 189 
known to be prognostically important.15  190 
Analysis of secondary outcomes, subgroup analyses and sensitivity analyses 191 
Analyses of secondary outcomes used regression models as appropriate. Consideration of potential effect 192 
modifiers employed formal tests of interaction. Sensitivity analyses considered multiple imputation of 193 
missing data (using a two-fold fully conditional specification algorithm),22 23 treatment adherence, day of 194 
recruitment, and inclusion of those with no moderately bad or worse cough at baseline (post-hoc). See 195 
Online Supplement for details.  196 
 197 
  198 
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RESULTS 199 
Enrolment and study population 200 
58 family physicians and 50 practice nurses based in 54 family practices assessed 525 patients for 201 
suitability, of whom 401 were eligible, consented and randomized: 199 to prednisolone and 202 to placebo 202 
(Figure 1), equating to a mean patient recruitment rate of 0.5 patients per month per practice. Two placebo 203 
group patients requested complete withdrawal immediately post randomization, and a further duplicate 204 
patient was subsequently identified in the prednisolone group (the participant remained in the group to 205 
which they were first allocated) leaving a sample of 398. The trial was stopped when the required number 206 
of participants was achieved. At baseline, participants had a mean age of 47.4 (SD 16.0) years; 37% were 207 
male; 3.5% had diabetes, 17% were currently smoking; 5% had received asthma medication more than 5 208 
years previously; 77% reported phlegm; 46% chest pain; 47% wheezing; 70% shortness of breath; and 42% 209 
had abnormal (defined as <80% expected) peak flow. Baseline characteristics were similar between the 210 
groups with respect to deprivation, smoking status, weight, height and clinical characteristics of the ALRTI, 211 
though compared to placebo, the prednisolone group were slightly more likely to be male, older (and 212 
hence retired), and to have received an influenza vaccine in the last 12 months (Table 1). 213 
 214 
Primary outcome data completeness 215 
Symptom diaries were returned by 374 (94%) participants (192 prednisolone and 182 placebo). For 216 
duration of moderately bad or worse cough, data were available in 334 (84%) participants with 40 reporting 217 
an initial cough severity <3 (that is, not moderately bad or worse) and 24 lost to follow up. For symptom 218 
severity, follow-up data were available in 370 (93%). However, one participant in the prednisolone group 219 
had no baseline measure of illness severity and could not be used in the adjusted analysis. Patients who 220 
withdrew or were lost to follow up were younger (median 30 years vs. 49 years), less likely to be white 221 
(85% vs 97%), more likely to be employed (86% vs. 69%) and higher English Index of Multiple Deprivation 222 
score (18 vs. 11). 223 
 224 
Primary analyses 225 
Moderately bad or worse cough duration 226 
The median duration of moderately bad or worse cough was 5 days (IQR, 3-8) in the prednisolone group 227 
and 5 days (IQR, 3-10) in the placebo group (Table 2). Kaplan Meier survival curves were similar for both 228 
groups (Figure 2). Visual inspection of the log-log survival curves and calculation of the Schoenfeld residuals 229 
(P=0.52) provided no evidence against proportional hazards. Comparing prednisolone with placebo, the Cox 230 
model adjusting for center and baseline cough duration resulted in a hazard ratio of 1.11 (95% CI 0.89, 1.39; 231 
P=0.36 with alpha of 0.05). The hazard ratio represents the instantaneous risk of resolution from 232 
moderately bad or worse cough in the prednisolone group compared to placebo; a hazard ratio greater 233 
than 1 demonstrates a beneficial effect of prednisolone. The Weibull AFT model time ratio was 0.91 (95% CI 234 
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0.76, 1.10) indicating that the time to resolution was reduced by 9% (0.45 days) with prednisolone 235 
compared to placebo (P=0.34); the lower limit of the 95% CI did not exclude the 20% a priori minimum 236 
clinically important difference. Further (secondary analysis) adjustment for factors demonstrating possible 237 
imbalance at baseline (age, gender, influenza vaccine in last 12 months) and smoking, had no effect on the 238 
models (Table 2).  239 
 240 
Day 2 to 4 symptom severity 241 
Mean symptom severity scores (and residuals) were normally distributed. The mean (SD) symptom severity 242 
scores were 1.99 (0.99) and 2.16 (1.09) for the prednisolone and placebo groups respectively. Adjusting for 243 
center and baseline illness severity, the mean symptom severity difference was 0.20 (95% CI -0.40, 0.00, 244 
P=0.05) between prednisolone and placebo (Table 2, a priori alpha 0.001). With a mean symptom severity 245 
score of 2.16 in the placebo group, a difference of 0.20 equates to a relative reduction of 9.3%. The lower 246 
limit of the 95% CI of this reduction was 18.5%, and excluded the 20% a priori minimum clinically important 247 
difference. Additional adjustment for factors demonstrating imbalance at baseline and smoking, marginally 248 
attenuated the difference in means and reduced the strength of evidence against the null hypothesis (Table 249 
2). 250 
 251 
Sensitivity analyses (see Online Supplement) 252 
None of the sensitivity analyses had any effect on the primary comparisons: including those with no 253 
moderately bad or worse cough at baseline; multiple imputation of missing data; per protocol analysis; 254 
adjusting for day of recruitment (Web Table 1). 255 
 256 
Secondary outcomes 257 
There were no significant effects on any symptom duration or peak flow up to 28 days, or cough duration 258 
to 56 days (Table 3). Neither were any significant effects observed for: antibiotic use; patient satisfaction or 259 
intention to use the same treatment if it were to be available in the future; non-serious adverse events 260 
(Table 3), expected, unexpected or cough-related adverse events, or reconsultations (Web Table 2). The 261 
nature of the adverse events was similar between the groups (Web Table 3), no new urinary or visual 262 
symptoms were reported, and none of the patients reporting fatigue, thirst and dry throat (Web Table 3) 263 
had diabetes. There were no serious adverse events. Four participants (3 prednisolone and 1 placebo) 264 
attended accident and emergency but were not hospitalized.  265 
 266 
Absolute measures of between-group differences 267 
To aid interpretation, Table 4 presents absolute measures of effect for the primary outcome of duration of 268 
moderately bad or worse cough and the time-to-event secondary outcomes reported in Table 3. There is no 269 
single absolute measure of treatment effect for time-to-event data as it will vary over the duration of 270 
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follow-up; it can, however, be calculated at a specific time point. Of particular clinical interest is day 7, 271 
because this is a time in the illness trajectory when clinicians and patients want to know about expected 272 
benefits, and when steroids should have affected symptoms if effective. Survival curves were produced 273 
from the Cox regressions presented in Tables 2 and 3 at given values of center (Bristol) and duration of 274 
prior cough (median value). Predicted survival probabilities at day 7 in the prednisolone and placebo groups 275 
were obtained and an absolute risk difference estimated as the survival probability in the prednisolone 276 
group minus that in the placebo group. 95% confidence intervals were obtained using the method 277 
proposed by Altman and Andersen.24 As an example of interpretation, for duration of moderately bad or 278 
worse cough the absolute difference in percentage unresolved at day 7 is -3.61 (95% CI -10.64, 4.23); this 279 
can be interpreted as 3.61% fewer prednisolone patients who still have an unresolved moderately bad or 280 
worse cough at the end of day 7. Absolute risk differences were also obtained (with 95% confidence 281 
intervals) for the binary secondary outcomes of antibiotic use (up to 7 and 28 days), patient satisfaction and 282 
intention to use the same treatment if it were to be available. 283 
 284 
Subgroup analyses 285 
All 95% confidence intervals for the interaction effects included values consistent with no significant 286 
subgroup effect (Web Table 4).   287 
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DISCUSSION 288 
In this randomized trial of 401 adults, five days of moderate dose oral prednisolone did not reduce the 289 
duration of moderately bad or worse cough, or the severity of symptoms between days 2 and 4, in non-290 
asthmatic adults who presented to primary care with ALRTI. Neither were any effects observed for the 291 
duration and severity of any ALRTI symptom, the duration of abnormal peak flow, antibiotic consumption 292 
or adverse events, including worsening of glycemic control in patients with diabetes. 293 
 294 
The study has several strengths. It was an adequately powered, multicenter, fully masked, randomised trial, 295 
with low rates of missing baseline and follow up data. The design was pragmatic, using eligibility criteria 296 
easily reproduced in routine clinical practice and clinically relevant, validated18 outcomes. The final sample 297 
included participants with high rates self-reported sputum production and wheeze, and was generalizable 298 
to non-asthmatic adults presenting to primary care with ALRTI in whom an immediate antibiotic is not 299 
necessary. With 398 participants, this trial more than doubles the number of patients recruited to primary 300 
care trials of corticosteroids for ALRTI,15 and to our knowledge, is the first to investigate the effects of oral 301 
rather than inhaled steroids. The trial also contributes to a growing body of evidence suggesting systemic 302 
and topical corticosteroids have a limited role in the treatment of common infections and their post-303 
infectious complications in primary care.25,26 This contrasts with an increasing number of studies suggesting 304 
corticosteroids are effective for secondary care patients with community acquired pneumonia27 croup,28 305 
acute sinusitis 29 and severe sore throat.30 306 
 307 
This study also has several limitations. First, the low patient recruitment rate suggests patients may have 308 
been selectively invited to participate, affecting the generalizability of the final sample. However, the rate 309 
was faster than a similar previous trial,19 not all practices were active throughout the recruitment period, 310 
and the characteristics of the final sample appears representative of primary care adult patients with ALRTI. 311 
Second, there were a higher than expected number of participants with zero duration of moderately bad or 312 
worse cough, though a sensitivity analysis including these participants did not influence the results. Third, 313 
other baseline biomarkers (e.g. inflammatory, microbiological, spirometric or radiographic) were not 314 
measured and it is possible that patients with more severe, inflammatory, eosinophilic31,32 or 315 
microbiological (e.g. rhinovirus)33 etiology entered the trial or could have differentially benefited. However, 316 
the study used readily recognized, pragmatic entry criteria facilitating replication in routine clinical practice. 317 
Fourth, study eligibility criteria might have included some patients with chronic or postinfectious cough, 318 
rather than ALRTI. However, 100% of participants had evidence of active lower respiratory tract 319 
involvement (sputum, shortness of breath, wheeze or chest pain) and over 75% had a pre-consultation 320 
cough duration <21 days. Fifth, the study used a patient-reported outcome rather than an objective 321 
primary outcome measure (such as digitally measured cough severity). This was chosen because it was 322 
considered the strongest option in the presence of a fully masked intervention; it closely reflected patient 323 
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priorities; and it allowed comparison with other trials.4,19 Sixth, the lack of effects and a similar between-324 
group pattern of adverse events could reflect poor adherence. However, this is unlikely as standard 325 
methods34 were used to establish similar and high levels of adherence to both prednisolone and placebo, 326 
and adverse events were similar to another trial in which a similar dose of prednisolone was proven 327 
effective.34 328 
 329 
The trial suggests oral corticosteroids should not be used in non-asthmatic/non-COPD adults in primary 330 
care who do not require treatment with an immediate antibiotic. Further research is needed to establish 331 
effectiveness in primary care patients with more severe infections, such as those with raised C-reactive 332 
protein, or requiring immediate antibiotic treatment, and larger studies or meta-analysis are needed to 333 
address effects in subgroups, such as those with longer pre-consultation illness and non-smokers.15  334 
 335 
Conclusions 336 
Among adults without asthma who developed ALRTI, the use of oral prednisolone for five days did not 337 
reduce symptom duration or severity. These findings do not support oral steroids for treatment of ALRTI in 338 
the absence of asthma. 339 
  340 
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TABLES 387 
 388 
Table 1. Baseline characteristics of randomized patients, by treatment group 389 
 Prednisolone 
(N=198) 
Placebo 
(N=200) 
Center, n (%)   
Bristol 118 (60%) 113 (57%) 
Oxford 39 (20%) 45 (23%) 
Southampton 24 (12%) 21 (11%) 
Nottingham 17 (9%) 21 (11%) 
Demographics and past medical history 
Gender, n (%) male 82 (41%) 66 (33%) 
Age in years, mean (SD) 50.0 (16.1) 44.8 (15.5) 
Weight kg, median (IQR)a 77.0 (64.5,91.0) 76.0 (66.5,90.5) 
Height cm, median (IQR)b 168.0 (161.0,175.0) 168.0 (163.0,176.0) 
Ethnicity, n (%) whitec 188 (95%) 193 (97%) 
Occupation, n (%)   
Employed 137 (69%) 143 (72%) 
Unemployed 17 (9%) 21 (11%) 
Retired 41 (21%) 30 (15%) 
Full-time education 3 (2%) 6 (3%) 
Deprivation (IMD)d, median (IQR)e 11.0 (5.0,23.0) 12.0 (5.0,23.0) 
Smoking status, n (%)f   
Current  31 (16%) 38 (19%) 
Past  63 (32%) 55 (28%) 
Never 104 (53%) 106 (53%) 
Lives with smoker, n (%)g 25 (14%) 32 (16%) 
Received asthma medication >5 years previouslyh 10 (5%) 8 (4%) 
Personal history of hay feveri 41 (22%) 46 (24%) 
Personal history of eczemaj 30 (16%) 26 (14%) 
Family history asthma or hay fever or eczema,    n (%)k 73 (40%) 76 (40%) 
Influenza vaccine in last 12 months, n (%) 63 (32%) 44 (22%) 
Recruited in winter (1st Oct-31st March) 112 (57%) 114 (57%) 
Clinical characteristics and management 
Prior duration of cough (days), median (IQR) 13.0 (7.0,20.0) 10.0 (6.0,17.5) 
Sputum (present within last 24 hours), n (%)l 149 (76%) 156 (78%) 
Shortness of breath (present within last 24 hours) n 
(%) 
146 (74%) 133 (67%) 
Wheeze (present within last 24 hours), n (%)l 88 (45%) 98 (49%) 
Chest pain (present within last 24 hours) n (%) 88 (44%) 97 (49%) 
Patient reported illness severity at assessment (0-10), 
median (IQR)m 
6.0 (5.0,7.0) 5.0 (4.0,7.0) 
Pulse rate (bpm), mean (SD) 77.8 (12.3) 77.7 (11.8) 
Temperature (⁰C), mean (SD) 36.6 (0.5) 36.6 (0.4) 
Oxygen saturation (%), mean (SD)n 97.5 (1.3) 97.8 (1.1) 
Abnormal peak flow (less than 80% of expected peak 87 (44%) 79 (40%) 
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flow)o 
Respiratory rate (breaths per minute)p 15.4 (2.5) 15.0 (2.4) 
Abnormal respiratory rate (more than 20 breaths per 
minute), n (%) 
2 (1%) 1 (1%) 
Chest retraction or prolonged expiration  0 (0%) 1 (1%) 
Wheeze or rhonchi (auscultation), n (%)  11 (6%) 11 (6%) 
Crackles or crepitations (auscultation), n (%)q 4 (2%) 6 (3%) 
Bronchial breathing, n (%)  0 (0%) 2 (1%) 
Taken prescribed β agonist in past 24 hours, n (%) 9 (5%) 3 (2%) 
Over-the-counter drugs taken for current cough, n (%) 128 (65%) 139 (70%) 
Given delayed antibiotic prescription, n (%) 22 (11%) 25 (13%) 
a Weight missing for 2 prednisolone participants 390 
b Height missing for 1 prednisolone participant 391 
c Ethnicity missing for 1 placebo participant 392 
d English Index of Multiple Deprivation scores (2015) [Geoconvert: UK Data Service Census Support], possible range 0-393 
100; higher scores indicate higher levels of deprivation 394 
e IMD missing for 2 prednisolone and 7 placebo participants  395 
f Smoking status missing for 1 placebo participant 396 
g Living with smoker missing for 15 prednisolone and 5 placebo participants 397 
h Personal history of asthma missing for 10 prednisolone patients and 7 placebo patients 398 
i Personal history of hayfever missing for 10 prednisolone patients and 11 placebo patients 399 
j Personal history of eczema missing for 14 prednisolone patients and 10 placebo patients 400 
k Family history of hay fever or eczema or asthma missing for 16 prednisolone and 11 placebo participants  401 
l Sputum and wheeze presence in last 24 hours, missing for 1 prednisolone participant 402 
m Patient reported illness severity 0 (completely well) to 10 (extremely unwell), missing for 1 prednisolone participant 403 
n Oxygen saturation missing for 1 prednisolone participant 404 
o Baseline abnormal peak flow was missing for 1 prednisolone patient 405 
p Respiratory rate missing for 2 prednisolone and 1 placebo patient as only collected for those with a ‘normal’ rate 406 
q Includes unilateral and bilateral  407 
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Table 2. Primary analyses 408 
 Prednisolone Placebo Prednisolone vs. placebo 
N Median (95% CI) N Median (95% CI) Hazard ratio  
(95% CI) 
P value 
(alpha=0.05) 
Time Ratioa  
(95% CI) 
P value 
(alpha=0.05) 
Duration (days) of moderately bad or 
worse cough (censored at 28 days) 
173 5 (4,5) 161 5 (4,6)     
Adjusted for center and baselineb     1.11 (0.89, 1.39)  0.36 0.91 (0.76, 1.10)  0.34 
Secondary additional adjustmentc,d     1.09 (0.87, 1.37)  0.44 0.92 (0.76, 1.12)  0.40 
 N Mean  
(95% CI) 
N Mean  
(95% CI) 
Difference in means (95% CI) P value  
(alpha=0.001) 
Mean symptom severity score (days 2-4)e 188 1.99 (1.85, 2.13) 181 2.16 (2.00, 2.32)   
Adjusted for center and baselineb,f     -0.20 (-0.40, 0.00) 0.054 
Secondary additional adjustmentc,d,f     -0.17 (-0.37, 0.04) 0.110 
a Time ratio can be interpreted as the relative increase or decrease in time to resolution of moderately bad or worse cough in the prednisolone group compared to placebo group 409 
b Baseline measure for duration of cough is prior duration of cough (1-28 days) and for mean symptom severity score is patient reported illness severity (0 – 10).  410 
c Adjusted for center, baseline (as detailed in footnote b), factors showing baseline imbalance (age, gender, influenza vaccine) and smoking  411 
d Smoking status missing for 1 placebo participant 412 
e See Methods, Primary Outcomes for derivation of mean symptom severity score (minimum of 0 and maximum of 6 (most severe)). 413 
f Patient reported illness severity missing for 1 prednisolone participant 414 
 415 
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Table 3. Secondary outcomes  416 
 Prednisolone 
(N=192) 
Placebo 
(N=182) 
Prednisolone vs. placebo 
Adjusted for center and baselinea 
Mean area under curveb,c 
(95% CI) 
Mean area under curveb,c 
(95% CI) 
Difference in mean area under curve 
(95% CI)  
P value 
Cough 40.16 (36.67, 43.65) 42.88 (38.88, 46.87) -2.43 (-7.66, 2.80) 0.36 
Phlegm 25.48 (22.19, 28.78) 30.01 (26.40, 33.61) -4.10 (-8.89, 0.70) 0.09 
Shortness of breath 16.10 (13.25, 18.95) 18.39 (15.16, 21.61) -2.30 (-6.34, 1.75) 0.27 
Wheeze 12.32 (9.69, 14.96) 13.24 (10.37, 16.11) 0.18 (-3.27, 3.64) 0.92 
Blocked or runny nose 19.83 (16.38, 23.28) 20.06 (17.12, 23.00) 0.67 (-3.70, 5.05) 0.76 
Chest pain 6.64 (4.95, 8.33) 9.59 (6.98, 12.19) -2.92 (-5.83, -0.01) 0.05 
Fever 2.98 (2.05, 3.91) 3.45 (2.07, 4.82) -0.33 (-1.90, 1.24) 0.68 
Muscle ache 8.83 (6.71, 10.96) 10.29 (7.53, 13.06) -1.61 (-4.99, 1.77) 0.35 
Headache 10.77 (8.27, 13.28) 11.83 (8.89, 14.77) -0.62 (-4.34, 3.09) 0.74 
Sleep disturbance 20.80 (17.66, 23.94) 22.11 (18.13, 26.10) -0.75 (-5.60, 4.10) 0.76 
Feeling generally unwell 19.83 (17.22, 22.45) 22.68 (19.17, 26.19) -3.25 (-7.38, 0.89) 0.12 
Activity disturbance 14.29 (12.01, 16.57) 19.07 (15.40, 22.74) -4.78 (-8.86, -0.69) 0.02 
 Median (95% CI)g Median (95% CI)g Hazard ratio (95% CI)  P value 
Duration (days) of moderately bad or 
worse cough (censored at 56 days)d 
5 (4,5) 5 (4,6) 1.11 (0.89, 1.39)  0.36 
Duration (days) of any cough (censored 
at 56 days)e 
18 (17,23) 20 (17, 25) 1.13 (0.90, 1.42)  0.29 
Duration (days) of abnormal peak flow 
(censored at 28 days)f 
10 (7, 17) 11 (8,17) 1.10 (0.79, 1.52)  0.58 
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a Baseline measure for cough area under curve (AUC), duration of moderately bad or worse cough (56 days), any cough (56 days) and abnormal peak flow is prior duration of cough 417 
(days); for all symptoms (AUC) (with the exception of cough) baseline measure is presence or absence of symptom at baseline (previous 24 hours); and for antibiotic consumption, 418 
whether participant given delayed antibiotic prescription (Y/N). No baseline measures available for patient satisfaction, taking tablets in future or adverse events. 419 
b For derivation of symptom area under curve see Online supplement: Methods, Statistical analyses, Analysis of secondary outcomes.35   420 
c Missing data - AUC analysis includes: 185 prednisolone and 179 placebo participants for cough; 184 prednisolone and 179 placebo participants for phlegm, shortness of breath; 421 
183 prednisolone and 179 placebo participants for wheeze, sleep disturbance; 182 prednisolone and 179 placebo participants for blocked or runny nose, chest pain, fever, muscle 422 
ache, headache, feeling generally unwell, activity disturbance. 423 
d 5 patients in each group had unresolved moderately bad or worse cough at day 28. Total duration (up to 56 days) obtained for 3 prednisolone and 5 placebo patients. 424 
e 61 prednisolone and 63 placebo patients had unresolved cough (score<1) at day 28. Total duration (up to 56 days) obtained for 38 prednisolone and 50 placebo patients. 425 
f 18 prednisolone and 25 placebo patients had abnormal peak flow at 28 days. Post-hoc sensitivity analysis removed 6 prednisolone patients rated at baseline as poor at measuring 426 
peak flow – there was no impact on the model. 427 
g Missing data - Duration of moderately bad or worse cough (56 days) analysis includes 173 prednisolone and 161 placebo participants (participants without moderately bad or 428 
worse cough on day 1 excluded); duration of any cough (56 days) analysis includes 191 prednisolone and 182 placebo participant; duration of abnormal peak flow analysis includes 429 
117 prednisolone and 115 placebo participants (participants with normal peak flow on day 1 excluded). 430 
h For derivation see Online supplement: Methods, Statistical analyses, Analysis of secondary outcomes  431 
i Missing data - Antibiotic consumption analyses include 191 prednisolone and 182 placebo participants; patient satisfaction analyses include 178 prednisolone and 171 placebo. 432 
j Excludes the duplicate participant who did experience an expected adverse event during their duplicate entry 433 
k Ordinal logistic regression, adjusting for center and baseline patient reported illness severity, missing for 1 participant. 434 
Table 3 continued     
 Prednisolone 
(N=192) 
Placebo 
(N=182) 
Prednisolone vs. placebo 
Adjusted for center and baselinea 
 n, (% {95% CI})i n, (% {95% CI})i OR (95% CI)  P value 
Consumption of antibiotics 
Up to 7 days 
Up to 28 days 
 
15, (8 {4, 12}) 
28, (15 {10, 20}) 
 
15, (8 {4, 12}) 
34, (19 {13, 24}) 
 
0.98 (0.42, 2.28) 
0.78 (0.44, 1.39) 
 
0.96 
0.39 
Patient satisfaction: Participant agrees 
trial tablets helped them feel betterh 
60, (34 {27, 41}) 43, (25 {19, 32}) 1.46 (0.92, 2.34) 0.11 
Participant agrees they would take trial 
tablets in futurei 
99, (56 {48, 63}) 81, (47 {40, 55}) 1.36 (0.89, 2.08) 0.16 
Any adverse eventsj 
0 
1 
>1 
 
151 (77 {71, 83}) 
36 (18 {13, 25}) 
9 (5 {2, 9}) 
 
162 (82 {76, 87}) 
24 (12 {8, 17}) 
12 (6 {3, 10}) 
 
1.26 (0.77, 2.07)k 
 
0.36 
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Table 4: Estimates of absolute between-group differences for time-to-event and binary outcomes 435 
 
 
Time-to-event outcomes 
Prednisolone Placebo Absolute difference in % 
unresolvedb (95% CI)  
Adjusted for center and baselinec 
 
Na 
Unresolved at end of day 7  
Na 
Unresolved at end of day 7 
n % (95% CI) n % (95% CI) 
Duration (days) of moderately bad or 
worse cough 
173 51 30.64 (23.89, 37.63) 161 44 29.19 (22.33, 36.38) -3.61(-10.64, 4.23) 
Duration (days) of any cough 191 164 88.36 (82.86, 92.18) 182 154 88.91 (83.34, 92.70) -1.28 (-4.07, 1.00) 
Duration (days) of abnormal peak flow  117 62 59.26 (49.56, 67.71) 115 63 60.32 (50.67, 68.67) -2.89 (-14.10, 6.83) 
Binary outcomes Na n % (95% CI) Na n % (95% CI) Absolute difference in % (95% CI)  
Adjusted for center and baselined 
Consumption of antibiotics 
Up to 7 days 
Up to 28 days 
191  
15 
28 
 
7.85 (4.00, 11.70) 
14.66 (9.60, 19.72) 
182  
15 
34 
 
8.24 (4.21, 12.28) 
18.68 (12.96 24.40) 
 
-0.09 (-5.13, 4.94) 
-3.26 (-10.53, 4.02) 
Patient satisfaction: Participant agrees 
trial tablets helped them feel better 
178 60 33.71 (26.70, 40.72) 171 43 25.15 (18.88, 31.71) 7.74 (-1.85, 17.34) 
Participant agrees they would take trial 
tablets in future 
178 99 55.62 (48.25,62.99) 171 81 47.37 (39.81, 54.93) 7.48 (-3.02, 17.97) 
a N refers to the number of participants with data available for the outcome of interest and included in the analysis. 436 
b Absolute difference is calculated as the percentage unresolved at end of day 7 in prednisolone group minus the percentage in placebo group. A negative value for the absolute 437 
risk difference indicates that a smaller percentage of prednisolone patients will have unresolved cough or abnormal peak flow at end of day 7 than placebo patients.  438 
c For time-to event outcomes adjusted analyses consider an ‘average’ value of covariates: Center = Bristol (where 60% of patients were recruited from) and prior duration of cough 439 
= 12 days (median value in sample). 440 
d Baseline measure for consumption of antibiotics is whether participant was given delayed antibiotic prescription at baseline (Y/N). No baseline measures available for patient 441 
satisfaction or taking tablets in future. 442 
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